Partnership with IBM Watson :
Intelligence artificielle (prostate)
Villepinte (France) and Cambridge (USA) – July 10, 2018 (8:30 am CEST) – Guerbet a global specialist in contrast agents and solutions for diagnostic and interventional medical imaging, today announced that it has signed an exclusive joint development agreement to develop an artificial intelligence (AI) software solution in collaboration with IBM Watson Health to support liver cancer diagnostics, utilizing CT and MRI imaging, and care.
Intelligence artificielle (liver)
Villepinte (France) and Cambridge (USA), September 24, 2019 (8:30 CEST) – Guerbet, a global specialist in contrast agents and solutions for diagnostic and interventional medical imaging, today announced that it has signed a new agreement with IBM Watson Health to co-develop and co-commercialize an artificial intelligence (AI) solution to help clinicians diagnose and monitor patients with prostate cancer.
(European eXcellence in interventional Oncology for HCC management)
With over 800,000 new cases worldwide every year,
hepatocellular carcinoma (HCC) remains a cancer
with a huge medical need, necessitating improved
practices at the various stages of the disease and
the patient pathway.
What is EXIOH
EXIOH (European eXcellence in Interventional Oncology for HCC management), a multidisciplinary initiative generating insights and solutions to improve Hepatocellular Carcinoma care management.
As a leader in the HCC field, Guerbet contributed
to the enhancement of physicians’ knowledge
by supporting an educational program entitled HCC days in five major European countries in the years 2018-2019. Continuing its partnership with the LaForce company, Guerbet supports a new educational program entitled EXIOH (European eXcellence in Interventional Oncology for Hcc treatment) to strengthen our partnerships with HCC reference centers and prepare new therapeutic paradigms, but also to identify solutions covering the gaps within the patient pathway.